Drugs Containing Excipient (Inactive Ingredient) DIMETHYL SULFOXIDE

« Back to Dashboard

Branded drugs containing DIMETHYL SULFOXIDE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	PENNSAID	diclofenac sodium	16590-453	DIMETHYL SULFOXIDE
Heron Therapeutics Inc	ZYNRELEF	bupivacaine and meloxicam	47426-301	DIMETHYL SULFOXIDE	2035-04-20
Teva Pharmaceuticals USA Inc	UZEDY	risperidone	51759-305	DIMETHYL SULFOXIDE

Generic drugs containing DIMETHYL SULFOXIDE excipient

Company	Ingredient	NDC	Excipient
Novartis Pharmaceuticals Corporation	tisagenlecleucel	0078-0846	DIMETHYL SULFOXIDE
Aurolife Pharma LLC	diclofenac sodium	13107-269	DIMETHYL SULFOXIDE
STAT RX USA LLC	diclofenac sodium	16590-453	DIMETHYL SULFOXIDE

Dimethyl Sulfoxide Pharmaceutical Excipient Market Dynamics and Financial Outlook

Last updated: October 12, 2026

Dimethyl sulfoxide, or DMSO, is a mature, low-cost pharmaceutical solvent and cryoprotectant with limited standalone patent protection. Its commercial outlook is tied less to conventional drug formulation growth than to cell and gene therapy manufacturing, biologics cryopreservation, specialty drug delivery, and high-purity supply qualification. Industrial DMSO demand is substantially larger than pharmaceutical demand, which makes pharmaceutical-grade pricing sensitive to feedstock costs, production capacity, and supplier concentration.

Public companies do not generally report DMSO revenue separately. Market forecasts therefore vary widely and often combine pharmaceutical, industrial, electronic, agricultural, and laboratory grades. The most defensible financial view is a stable-to-moderate growth market with higher growth in GMP and cell-therapy grades than in bulk DMSO.

What is dimethyl sulfoxide used for in pharmaceutical manufacturing?

DMSO is a polar aprotic solvent with high water miscibility and the ability to dissolve many organic and inorganic compounds. Its principal pharmaceutical roles are:

Use	Commercial function	Growth outlook
Cryopreservation	Protects cells, tissues, stem cells, and some biologic materials during freezing	High
API and intermediate processing	Reaction solvent, extraction medium, crystallization aid, and process solvent	Low to moderate
Topical and transdermal delivery	Enhances skin penetration of selected active ingredients	Selective
Drug product formulation	Solvent or co-solvent in niche liquid and parenteral products	Low to moderate
Cell and gene therapy	Cryopreservation of cellular drug substances and intermediates	High
Veterinary medicines	Solvent and penetration enhancer	Moderate
Research and laboratory use	Solvent for assays, screening, and sample preparation	Moderate

DMSO is often removed during downstream processing. When it remains in the finished product, the manufacturer must control residual levels, odor, impurities, extractables, and patient tolerability.

DMSO has a strong odor and can cause local irritation or other tolerability concerns. Those characteristics limit its use in chronic administration and consumer-facing products. Glycerol, propylene glycol, ethanol, polyethylene glycols, and other cryoprotectants or co-solvents compete with DMSO in specific applications.

How large is the pharmaceutical-grade DMSO market?

There is no consistently reported public market figure for pharmaceutical-grade DMSO alone. Commercial market reports usually aggregate multiple grades and end uses, including industrial solvents, electronics, agriculture, pharmaceuticals, and laboratory chemicals.

The market should be analyzed in three layers:

1. Bulk DMSO, which is driven mainly by industrial and chemical-processing demand.
2. High-purity and pharmaceutical-grade DMSO, which commands higher pricing and requires documented impurity control.
3. GMP or cell-therapy-grade DMSO, which has the highest qualification requirements and the strongest growth profile.

Pharmaceutical-grade DMSO is a specialty segment by volume but a higher-value segment by unit price. In cell therapy, the cost of DMSO is usually small compared with the cost of manufacturing, testing, release, and logistics. Supplier qualification, regulatory documentation, sterility assurance, and lot-to-lot consistency are more important than raw material price.

What factors determine DMSO pricing?

DMSO pricing is affected by:

• Dimethyl sulfide feedstock availability.
• Sulfur and energy costs.
• Regional production capacity.
• Ocean freight and hazardous-material logistics.
• Purification requirements.
• Packaging size and container system.
• GMP documentation and audit requirements.
• Sterile filtration or sterile fill operations.
• Customer qualification and change-control obligations.

Bulk industrial DMSO is comparatively price competitive. GMP-grade DMSO has higher switching costs because a manufacturer may need to repeat formulation, process, stability, container-closure, or comparability work after changing suppliers.

What is driving DMSO demand in cell and gene therapy?

Cell and gene therapy is the strongest pharmaceutical growth driver for DMSO. The compound is widely used as a cryoprotectant for cell suspensions and cellular intermediates, including hematopoietic stem cells and some autologous and allogeneic cell therapy products.

Commercial demand is supported by:

• Growth in marketed cell therapies.
• Expansion of decentralized manufacturing and hospital-based administration.
• Larger clinical pipelines for CAR-T, T-cell receptor, stem-cell, and other cellular products.
• Development of closed-system manufacturing.
• Increased use of ready-to-use cryopreservation solutions.
• More stringent raw-material qualification by advanced-therapy manufacturers.

The main limitation is that DMSO is not universally required. Developers may pursue reduced-DMSO or DMSO-free formulations because of infusion reactions, nausea, hypotension, bradycardia, or other tolerability concerns. Alternative cryoprotectant systems include hydroxyethyl starch, trehalose, glycerol, albumin, and proprietary combinations.

The commercial result is bifurcated. Demand for qualified DMSO should rise with cell therapy production, while demand per dose may decline where manufacturers reduce DMSO concentration or remove it before administration.

What is the FDA regulatory status of DMSO?

DMSO has an established FDA drug product history but should not be treated as a generally approved excipient for every route or dosage form.

The FDA-approved product RIMSO-50 contains dimethyl sulfoxide and is indicated for symptomatic relief in patients with interstitial cystitis. The product is administered intravesically and has a long-standing U.S. labeling history. Its existence supports the established pharmaceutical status of DMSO as an active pharmaceutical ingredient in a specific product, not blanket approval for all excipient applications.[1]

For excipient use, sponsors must establish suitability for the intended route, concentration, formulation, and manufacturing process. Relevant considerations include:

• Compendial identity and purity.
• Residual solvents and related impurities.
• Water content.
• Elemental impurities.
• Microbial and endotoxin controls where applicable.
• Container compatibility.
• Extractables and leachables.
• Toxicological exposure.
• Stability and degradation behavior.
• Residual DMSO in the final product.

The FDA Inactive Ingredient Database can support regulatory precedent where a particular DMSO use, route, and dosage form are listed. The database does not eliminate the sponsor’s responsibility to justify the proposed level and product-specific exposure.[2]

What is the pharmacopoeial status of pharmaceutical-grade DMSO?

DMSO is covered by major pharmaceutical quality systems and compendial frameworks, including the United States Pharmacopeia-National Formulary and other national or regional pharmacopoeias. A supplier’s claim that material is “USP,” “Ph. Eur.,” or “compendial” must be matched to a current certificate of analysis and the exact material specification.

Pharmaceutical buyers typically evaluate:

Quality attribute	Relevance
Assay	Confirms DMSO concentration
Water content	Affects stability and process performance
Acidity or alkalinity	Indicates contamination or degradation
UV absorbance	Screens organic impurities
Residue on evaporation	Detects nonvolatile contaminants
Related substances	Controls oxidation and process impurities
Heavy metals or elemental impurities	Supports ICH risk assessment
Microbial quality	Important for sterile or parenteral applications
Endotoxins	Relevant to cell and parenteral manufacturing
Particulates	Relevant to injectable and cell-therapy use

Cell-therapy manufacturers often require more extensive documentation than a basic compendial certificate. A product may be chemically compliant but still unsuitable for a GMP process if the supplier lacks change-control procedures, audit support, traceability, validated analytical methods, or appropriate packaging.

What patents protect dimethyl sulfoxide pharmaceutical uses?

The DMSO molecule is not protected by a commercially relevant composition-of-matter patent. It has been known and used for decades. Any original compound-level exclusivity has expired.

Current patent value, where it exists, generally lies in:

• Specific DMSO-containing formulations.
• Cryopreservation mixtures.
• DMSO-reduction or DMSO-removal processes.
• Cell-processing workflows.
• Drug-delivery combinations.
• Specific therapeutic methods.
• Container or delivery systems.
• Manufacturing processes involving DMSO.

These rights protect a product or process that uses DMSO rather than DMSO itself. Their commercial strength depends on claim scope, enablement, prosecution history, freedom-to-operate findings, and whether the relevant product is commercially important.

Are there DMSO formulation patents?

Yes. DMSO appears in patents covering topical compositions, transdermal delivery, ophthalmic systems, injectable formulations, cryopreservation media, and cell-processing methods. The patent landscape is fragmented and application-specific.

A DMSO formulation patent may be weak if:

• The claims rely on broad concentration ranges.
• The composition uses well-known excipients.
• The specification provides limited examples.
• The claims are vulnerable to obviousness arguments.
• The product can be redesigned without using the claimed combination.

A stronger patent position may arise where DMSO is integrated into a validated cryopreservation workflow, a defined cell-processing method, or a specific combination with a proprietary active ingredient.

When does DMSO lose exclusivity?

DMSO has no meaningful remaining molecule-level exclusivity. Pharmaceutical products containing DMSO may have product-specific patents, regulatory exclusivity, or formulation protection, but those rights do not create exclusivity over the excipient.

Exclusivity category	DMSO position
Compound patent	Expired or commercially irrelevant
Excipient composition patent	Generally unavailable for DMSO itself
Formulation patent	Possible, but product-specific
Method-of-use patent	Possible for selected indications
Manufacturing patent	Possible for specialized processes
FDA new chemical entity exclusivity	Not applicable to established DMSO
Orphan-drug exclusivity	Possible only for a qualifying DMSO-containing product
Biosimilar exclusivity	Not applicable
Generic drug exclusivity	Applies to a finished drug product, not bulk DMSO

What is the Orange Book status of DMSO?

The Orange Book is relevant to approved finished drug products, not to bulk excipients as a category. RIMSO-50 is the principal U.S. reference point for DMSO as an approved drug substance and product. Orange Book analysis should focus on the specific listed product, its approved labeling, any listed patents, and any regulatory exclusivity.

A DMSO supplier does not obtain Orange Book protection merely by selling USP or GMP-grade DMSO. A finished-drug sponsor must establish its own product approval and any applicable patent listing.

Are there Paragraph IV challenges involving DMSO?

Paragraph IV litigation is generally associated with an abbreviated new drug application challenging patents listed for a reference drug. It is not a normal feature of bulk DMSO supply.

A generic sponsor seeking to market a DMSO-containing finished product could submit a Paragraph IV certification if relevant patents are listed for the reference product. That risk would depend on the product’s dosage form, route, formulation, labeling, and listed patents. It does not apply to ordinary procurement of DMSO as a raw material.

No broad Paragraph IV barrier protects the pharmaceutical-grade DMSO market. Competitive risk is driven by supplier qualification and product-level patents rather than excipient exclusivity.

Which companies supply pharmaceutical-grade DMSO?

The supply base includes chemical manufacturers, laboratory reagent companies, pharmaceutical excipient distributors, and specialty GMP suppliers. Representative market participants include:

• Gaylord Chemical.
• Toray Fine Chemicals.
• Merck and Sigma-Aldrich.
• Thermo Fisher Scientific.
• Avantor.
• Spectrum Chemical.
• TCI Chemicals.
• Regional Asian chemical producers and distributors.

The relevant distinction is between a manufacturer and a reseller. A catalog supplier may provide laboratory-grade DMSO without offering the quality agreement, regulatory package, traceability, audit access, and change notification required for commercial pharmaceutical manufacturing.

Supplier concentration is higher for validated GMP and sterile grades than for bulk material. Manufacturers of cell therapies often dual-source early, but qualification of a second supplier can take months or longer when the raw material is used in a regulated manufacturing process.

What manufacturing and intellectual-property barriers affect DMSO?

DMSO is commonly produced by oxidation of dimethyl sulfide. Production economics depend on feedstock integration, purification capacity, environmental controls, and access to chemical infrastructure.

The main barriers are operational rather than patent-based:

1. Consistent purity at pharmaceutical specifications.
2. Control of oxidation-related impurities.
3. Validated cleaning and contamination controls.
4. Reliable batch documentation.
5. Secure hazardous-material transportation.
6. Packaging compatible with DMSO’s solvent properties.
7. Change-control discipline.
8. Sterile or low-bioburden capability for advanced therapies.

DMSO can interact with plastics, elastomers, coatings, and other materials. Container selection is therefore part of product qualification. Packaging failures, leachables, or changes in closure systems can trigger costly requalification.

How strong is the DMSO patent estate?

The estate is weak for the excipient itself and potentially moderate for selected applications.

Patent layer	Strength	Commercial implication
DMSO composition	Very low	No meaningful exclusivity
Bulk production	Low to moderate	Process know-how may matter more than patents
Topical formulations	Low to moderate	Design-around risk is high
Cryopreservation formulations	Moderate in defined combinations	Stronger when linked to cell-processing data
Cell-therapy manufacturing methods	Moderate to high in narrow cases	Product and process freedom-to-operate required
DMSO-reduction systems	Moderate	Potential differentiation for infusion tolerability
Packaging and delivery systems	Low to moderate	Protection is usually narrow

Patent litigation specifically directed at bulk DMSO is unlikely. Disputes are more likely to involve a finished product, cell-therapy process, or delivery system in which DMSO is one component.

How does DMSO compare with competing excipients?

Attribute	DMSO	Glycerol	Propylene glycol	Ethanol	Trehalose
Cryoprotection	Strong and widely established	Strong in selected systems	Limited to moderate	Limited to moderate	Strong in some biologic systems
Cell-therapy familiarity	High	Moderate	Low to moderate	Low	Increasing
Odor and tolerability	Material concern	Generally better	Generally better	Volatility and tolerability concerns	Generally favorable
Solvent power	High	Moderate	Moderate	High for many organics	Low
Regulatory history	Established but application-specific	Broad	Broad	Broad	Broadening
Cost	Low in bulk	Low	Low	Low	Higher in some grades
DMSO-reduction potential	Not applicable	Common alternative	Possible co-solvent	Possible co-solvent	Common alternative

DMSO remains difficult to displace where it delivers a combination of solvent power, membrane penetration, and cryoprotection that alternatives cannot match. Substitution is more likely where patient tolerability or product-labeling requirements favor lower DMSO exposure.

What generic launch risks exist for DMSO-containing products?

Generic entry risk is usually high for simple DMSO-containing products because the active ingredient is old, available from multiple suppliers, and not protected by molecule-level patents. Risk falls when the reference product has:

• A narrow or complex formulation.
• A device or specialized delivery system.
• A protected method of use.
• A difficult-to-reproduce manufacturing process.
• Product-specific clinical or stability requirements.
• Limited access to qualified GMP-grade material.

For RIMSO-50-type products, the main barriers are regulatory submission requirements, commercial scale, manufacturing economics, and market size rather than access to DMSO.

What is the financial trajectory for DMSO suppliers?

The financial trajectory is likely to diverge by grade and application.

Bulk and industrial DMSO

This segment should remain cyclical and margin-sensitive. Revenue depends on volume, feedstock prices, regional capacity, and industrial demand. Large producers with integrated supply chains have better cost positions than distributors.

Pharmaceutical and high-purity DMSO

This segment should grow faster than bulk DMSO if pharmaceutical manufacturing, biologics, and advanced therapies expand. Margins benefit from documentation, technical service, validated packaging, and customer qualification. Volume remains modest relative to industrial applications.

Cell-therapy-grade DMSO

This is the most attractive segment by growth rate but also has execution risk. Demand can be affected by clinical failures, manufacturing redesigns, DMSO-reduction programs, and the small number of commercial cell therapies relative to conventional medicines.

Public financial statements generally do not isolate DMSO sales. Revenue exposure must therefore be estimated from segment mix, production capacity, customer contracts, and grade-specific pricing rather than reported company-level DMSO revenue.

What litigation and settlement issues affect the market?

There is no broad DMSO patent settlement framework comparable to major small-molecule branded drugs. The relevant legal issues are more likely to involve:

• Supply agreements.
• Product specifications.
• Batch failures.
• Change-control disputes.
• Contamination claims.
• Confidential manufacturing know-how.
• Cell-therapy process patents.
• Formulation and method-of-use patents.
• Regulatory responsibility for raw-material changes.

A settlement involving a DMSO-containing finished drug would not necessarily affect the broader excipient market. Its effect would depend on whether the agreement restricted a formulation, manufacturing method, supplier, or indication.

What is the geographic outlook for DMSO?

Asia is central to global DMSO production and consumption, with China and Japan representing important manufacturing bases. North America and Europe remain significant pharmaceutical and advanced-therapy markets, even where local bulk production is limited.

Regional commercial considerations include:

Region	Market position
North America	Strong demand from cell therapy, biotechnology, and regulated drug manufacturing
Europe	Significant biologics and advanced-therapy manufacturing; strict supplier qualification
China	Important production base and expanding pharmaceutical demand
Japan	Established chemical manufacturing and high-purity supply capabilities
India	Growing pharmaceutical formulation and chemical-processing demand

Geographic diversification is valuable because DMSO supply can be affected by plant outages, logistics restrictions, chemical-sector downturns, and trade controls. Pharmaceutical buyers often maintain regional safety stock because qualification of replacement material is slow.

Key Takeaways

• DMSO is a mature, off-patent pharmaceutical solvent and cryoprotectant.
• The strongest pharmaceutical growth driver is cell and gene therapy manufacturing.
• GMP and cell-therapy grades have better pricing and margin potential than bulk industrial DMSO.
• Public market-size estimates are unreliable because most combine pharmaceutical and nonpharmaceutical grades.
• DMSO has no meaningful molecule-level exclusivity and is not protected as a bulk excipient by Orange Book patents.
• Formulation, method-of-use, cryopreservation, and manufacturing patents can protect specific products and processes.
• Generic entry barriers are usually low for simple DMSO-containing products.
• Supplier qualification, impurity control, packaging compatibility, and regulatory documentation are more important than patent barriers.
• DMSO-reduction and DMSO-free cryopreservation systems are the main long-term substitution risk.
• Financial performance is likely to be stable in bulk grades and stronger in qualified GMP grades linked to advanced therapies.

FAQs

Is DMSO an FDA-approved pharmaceutical excipient?

DMSO has an established FDA drug-product history, including RIMSO-50, but that does not constitute universal approval for every excipient use, route, concentration, or dosage form.

Is pharmaceutical-grade DMSO interchangeable between suppliers?

No. Chemical equivalence does not guarantee regulatory or manufacturing interchangeability. Supplier changes may require comparability testing, qualification, stability work, and regulatory assessment.

Does DMSO have an active pharmaceutical patent?

DMSO itself does not have meaningful active molecule-level patent protection. Patents may cover particular formulations, delivery systems, cryopreservation media, or manufacturing methods.

Can DMSO be used in injectable products?

It can be used in selected parenteral or cell-processing applications, but the sponsor must justify concentration, exposure, impurity profile, sterility controls, container compatibility, and patient tolerability.

What is the main investment risk in the DMSO market?

The principal risks are commodity pricing, supplier concentration, advanced-therapy pipeline volatility, DMSO-reduction technologies, and the absence of separately reported DMSO revenue at most public suppliers.

References

1. U.S. Food and Drug Administration. (2024). RIMSO-50: Dimethyl sulfoxide injection prescribing information. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. Center for Drug Evaluation and Research.

3. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.

4. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.

5. International Council for Harmonisation. (2022). ICH Q3C(R8): Impurities: Guideline for residual solvents. ICH.

6. U.S. Food and Drug Administration. (2020). Chemistry, manufacturing, and control information for human somatic cell therapy investigational new drug applications. Center for Biologics Evaluation and Research.

7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.